180 results on '"Zelniker, Thomas A."'
Search Results
2. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases
3. Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome
4. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
5. Positionspapier Herzinsuffizienz und Diabetes
6. Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial
7. Abstract 14870: Adrenomedullin in Patients With Out-of-Hospital Cardiac Arrest
8. Abstract 13069: Left Atrial Mechanics in Patients With Hypertrophic Cardiomyopathy
9. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization
10. Relationship between markers of inflammation and hemodynamic stress and death in patients with out-of-hospital cardiac arrest
11. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
12. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review
13. Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension
14. Abstract 16688: Effects of Evolocumab in Patients With Prior Percutaneous Coronary Intervention: An Analysis From the Fourier Trial
15. Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58
16. Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial
17. Prognostic Value of High-Sensitivity Cardiac Troponin T Compared with Risk Scores in Stable Cardiovascular Disease
18. Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide.
19. Response by Zelniker et al to Letter Regarding Article, “Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial”
20. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
21. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial
22. The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry
23. Fibroblast growth factor 23 (FGF-23) is an early predictor of mortality in patients with cardiac arrest
24. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
25. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial
26. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
27. Coronary Angiography After Out-of-Hospital Cardiac Arrest Without ST-Segment Elevation: One-Year Outcomes of a Randomized Clinical Trial.
28. The prognostic value of right ventricular long axis strain in non-ischaemic dilated cardiomyopathies using standard cardiac magnetic resonance imaging
29. Abstract 19116: Prognostic Performance of GDF-15 Across the Spectrum of Risk in Patients With NSTE-ACS Enrolled in MERLIN - TIMI 36
30. Abstract 17950: High-Dose Edoxaban Regimen versus Warfarin in Patients With Atrial Fibrillation and Established Coronary Artery Disease: Insights From the ENGAGE AF-TIMI 48 Trial
31. Mid-regional pro-adrenomedullin and lactate levels for risk stratification in patients with out-of-hospital cardiac arrest.
32. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.
33. Efficacy of enteral ticagrelor in hypothermic patients after out-of-hospital cardiac arrest
34. Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery.
35. Long‐term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction.
36. ELEVATED TUMOR MARKERS IN PATIENTS RECOVERED FROM SARS-COV-2 INFECTION WITH LONG-TERM CARDIOVASCULAR SYMPTOMS
37. EFFECT OF DOACS VERSUS WARFARIN BY ASCVD STATUS IN 58,634 PATIENTS WITH ATRIAL FIBRILLATION: A POOLED ANALYSIS OF 4 RANDOMIZED TRIALS
38. A novel prediction model for pulmonary embolism: from dichotomizing algorithms to personalized likelihood.
39. Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies
40. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
41. Relationship of diabetes, heart failure, and N‐terminal pro‐B‐type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation.
42. Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension
43. SGLT2 inhibitors in heart failure: insights from plasma proteomics.
44. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.
45. Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in heart transplantation.
46. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
47. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
48. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58.
49. Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36.
50. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.